2021 ASH Annual Meeting: CAR T-Cell Therapy
The 2021 ASH Annual Meeting: CAR T-Cell Therapy priority report is a digital version of the print publication spanning some of the groundbreaking abstracts in CAR T-cell therapy that were presented during the conference.
Cilta-cel Elicits Early, Deep Responses in Heavily Pretreated, Lenalidomide-Refractory Myeloma
December 15th 2021A single infusion of ciltacabtagene autoleucel produced an overall response rate of 95% in patients with multiple myeloma who had received a median of 2 prior lines of treatment and who were refractory to lenalidomide.
Axi-Cel Demonstrates 60% EFS Improvement in Second-Line Relapsed/Refractory LBCL
December 13th 2021Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.
Tisagenlecleucel Displays Promising Efficacy Results Across Subgroups in R/R FL
December 11th 2021Tisagenlecleucel produced a high overall response rate and complete response rate in adult patients with relapsed/refractory follicular lymphoma who had received 2 or more prior lines of therapy, according to results from an extended follow-up analysis of patients with at least 12 months of follow-up of the phase 2 ELARA trial.
Axi-Cel Demonstrates Ongoing Survival Benefit in Relapsed/Refractory iNHL
December 11th 2021Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.
Liso-cel Bests Standard of Care in Second-Line Treatment of LBCL
December 11th 2021Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.
